Alan Wickenden

Alan Wickenden

UNVERIFIED PROFILE

Are you Alan Wickenden?   Register this Author

Register author
Alan Wickenden

Alan Wickenden

Publications by authors named "Alan Wickenden"

Are you Alan Wickenden?   Register this Author

41Publications

710Reads

14Profile Views

Pharmacology of JNJ-28583113: A novel TRPM2 antagonist.

Eur J Pharmacol 2019 Jun 6;853:299-307. Epub 2019 Apr 6.

Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, CA, 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2019.03.043DOI Listing
June 2019

Potentiating SLC transporter activity: Emerging drug discovery opportunities.

Biochem Pharmacol 2017 07 16;135:1-11. Epub 2017 Feb 16.

Molecular and Cellular Pharmacology, Discovery Sciences, Janssen R&D, San Diego, CA 92121, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00062952173008
Publisher Site
http://dx.doi.org/10.1016/j.bcp.2017.02.010DOI Listing
July 2017

State-Dependent Allosteric Inhibition of the Human SLC13A5 Citrate Transporter by Hydroxysuccinic Acids, PF-06649298 and PF-06761281.

Mol Pharmacol 2016 Dec 17;90(6):766-774. Epub 2016 Oct 17.

Molecular and Cellular Pharmacology, Discovery Sciences, Janssen R&D, LLC., San Diego, California (M.-L.R., M.S., A.D.W.) and Cardiovascular and Metabolism Discovery, Janssen R&D, LLC., Springhouse, Pennsylvania, (B.Z., S.A.H.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.116.106575DOI Listing
December 2016

Discovery and Characterization of AMPA Receptor Modulators Selective for TARP-γ8.

J Pharmacol Exp Ther 2016 May 17;357(2):394-414. Epub 2016 Mar 17.

Janssen Research and Development, LLC, Neuroscience Therapeutic Area, San Diego, California (M.P.M., N.W., S.R., M.K.A., B.M.S., C.L., B.L., R.M.W., J.A.M., C.D., S.Y., A.D.W., N.I.C., T.W.L.); and Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Neuroscience Therapeutic Area, Beerse, Belgium (L.V.D., T.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.115.231712DOI Listing
May 2016

Two TRPV1 receptor antagonists are effective in two different experimental models of migraine.

J Headache Pain 2015 24;16:57. Epub 2015 Jun 24.

Department of Physiology, Uniklinik RWTH Aachen, Pauwelsstr. 30, D-52074, Aachen, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-015-0539-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491068PMC
February 2016

SCN9A Variants May be Implicated in Neuropathic Pain Associated With Diabetic Peripheral Neuropathy and Pain Severity.

Clin J Pain 2015 Nov;31(11):976-82

*Neuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville †Neuroscience Therapeutic Area, Janssen Research & Development, LLC, Raritan, NJ ‡Aranea, Janssen Research & Development, LLC, La Jolla, CA §Neuroscience Therapeutic Area, Janssen Research & Development, LLC, Spring House, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AJP.0000000000000205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894774PMC
November 2015

Overview of Electrophysiological Techniques.

Authors:
Alan D Wickenden

Curr Protoc Pharmacol 2014 Mar 3;64:11.1.1-17. Epub 2014 Mar 3.

Janssen R&D, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/0471141755.ph1101s64DOI Listing
March 2014

The physiology, pharmacology and future of P2X7 as an analgesic drug target: hype or promise?

Curr Pharm Biotechnol 2011 Oct;12(10):1698-706

Neuroscience, Johnson & Johnson Pharmaceutical Research & Development LLC., San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138920111798357429DOI Listing
October 2011

Discovery of a novel series of selective HCN1 blockers.

Bioorg Med Chem Lett 2011 Sep 23;21(18):5197-201. Epub 2011 Jul 23.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0960894X110098
Publisher Site
http://dx.doi.org/10.1016/j.bmcl.2011.07.051DOI Listing
September 2011

N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

ACS Med Chem Lett 2011 Jun 31;2(6):481-4. Epub 2011 Mar 31.

Departments of Chemistry, Pharmacology, and Biology, Icagen Inc. , 4222 Emperor Boulevard, Durham, North Carolina 27702, United States.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/ml200053x
Publisher Site
http://dx.doi.org/10.1021/ml200053xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018159PMC
June 2011

Recent advances in the biology and medicinal chemistry of TRPA1.

Future Med Chem 2010 May;2(5):843-58

Johnson & Johnson Pharmaceutical Research & Development, LLC, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://www.future-science.com/doi/10.4155/fmc.10.29
Publisher Site
http://dx.doi.org/10.4155/fmc.10.29DOI Listing
May 2010

Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.

J Med Chem 2010 Jan;53(2):887-96

Icagen, Inc., Suite 390, 4222 Emperor Boulevard, Durham, North Carolina 27703, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm901497bDOI Listing
January 2010

The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.

Neurosci Lett 2009 Nov 3;465(2):138-42. Epub 2009 Sep 3.

Icagen, 4222 Emperor Boulevard, Suite 460, Durham, NC 27703, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neulet.2009.08.071DOI Listing
November 2009

Sodium channel blockers for the treatment of neuropathic pain.

Neurotherapeutics 2009 Oct;6(4):663-78

Pain & Related Disorders Team, Johnson & Johnson Pharmaceutical Research & Development, LLC, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nurt.2009.08.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084288PMC
October 2009

Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.

Bioorg Med Chem Lett 2009 Jun 8;19(11):3063-6. Epub 2009 Apr 8.

Icagen Inc, NC 27709, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.04.002DOI Listing
June 2009

Intracellular zinc irritates TRPA1.

Nat Chem Biol 2009 Mar;5(3):141-2

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nchembio0309-141DOI Listing
March 2009

HCN channels as targets for drug discovery.

Comb Chem High Throughput Screen 2009 Jan;12(1):64-72

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138620709787048028DOI Listing
January 2009

Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms.

Comb Chem High Throughput Screen 2009 Jan;12(1):107-22

Icagen Inc., Durham, North Carolina 27703, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138620709787047993DOI Listing
January 2009

Activation of TRPA1 by farnesyl thiosalicylic acid.

Mol Pharmacol 2008 Apr 2;73(4):1225-34. Epub 2008 Jan 2.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.107.042663DOI Listing
April 2008

Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs.

J Pharmacol Exp Ther 2007 Nov 9;323(2):665-74. Epub 2007 Aug 9.

Department of Pain and Related Disorders, Johnson & Johnson Pharmaceutical Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.107.127258DOI Listing
November 2007

Distribution and functional properties of human KCNH8 (Elk1) potassium channels.

Am J Physiol Cell Physiol 2003 Dec 30;285(6):C1356-66. Epub 2003 Jul 30.

Icagen, Inc., 4222 Emperor Blvd., Durham, NC 27703, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpcell.00179.2003DOI Listing
December 2003

Electrophysiological analysis of heterologously expressed Kv and SK/IK potassium channels.

Curr Protoc Pharmacol 2003 May;Chapter 11:Unit11.5

Icagen, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/0471141755.ph1105s20DOI Listing
May 2003

K(+) channels as therapeutic drug targets.

Authors:
Alan Wickenden

Pharmacol Ther 2002 Apr-May;94(1-2):157-82

Icagen Inc., Suite 460, 4222 Emperor Boulevard, Durham, NC 27703, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0163-7258(02)00201-2DOI Listing
March 2003

Potassium channels as anti-epileptic drug targets.

Authors:
Alan D Wickenden

Neuropharmacology 2002 Dec;43(7):1055-60

Icagen Inc, Suite 460, 4222 Emperor Boulevard, Durham, NC 27703, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0028-3908(02)00237-xDOI Listing
December 2002

Myocardial infarction in rat eliminates regional heterogeneity of AP profiles, I(to) K(+) currents, and [Ca(2+)](i) transients.

Am J Physiol Heart Circ Physiol 2002 Sep;283(3):H1157-68

Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, Massachusetts 02129-0060, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajpheart.00518.2001DOI Listing
September 2002

Inhibition of calcineurin and sarcolemmal Ca2+ influx protects cardiac morphology and ventricular function in K(v)4.2N transgenic mice.

Circulation 2002 Apr;105(15):1850-6

Department of Physiology and the Division of Cardiology, University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/01.cir.0000014211.47830.4dDOI Listing
April 2002